Clinical Relevance of the Antimicrobial Resistance Testing in the Treatment of Chronic Wounds With Antiseptics (AntiSeptic)


RWTH Aachen University

Status and phase

Phase 3


Chronic Wounds
Acute Wounds


Drug: Octenisept and Serasept

Study type


Funder types



Details and patient eligibility


The study objective is to improve the current and local standard antiseptic treatment by adjusting the antiseptic agent to the antimicrobial resistance testing result, accordingly. Currently, resistance testing will only be performed for the treatment with antibiotics.

Full description

Complications like bacterial wound colonization and infections in wound treatment are still a serious problem. Several therapy approaches are available to treat these complications, e.g. surgical wound debridement, antimicrobial therapy that can be divided into a local and a systemic antisepsis.

The local antisepsis (the local utilization of antiseptics directly to the wound) is in many ways advantageous to the systemic antisepsis (orally or intravenously administered antibiotics): e. g. the direct contact of the antiseptic to the bacteria at the site of infection whereas antibiotics may not sufficiently reach the wound due to limited blood perfusion of wounds; growing utilization of systemic antisepsis also leads to an increasing number of resistant bacteria worldwide. To the concerns of many specialists, the first pan-resistant bacterial strain which is resistant to all available antibiotics including colistin was recently published.

In future, the role of local antisepsis therefore becomes more important in the antimicrobial treatment. Luckily, resistances of local antiseptics occur slowly due to the chemical and structural characteristics of antiseptics but even resistances of bacteria to antiseptics were reported. Unlike the antimicrobial resistance testing for antibiotics that is done in the clinical routine, such testing is not a standard procedure for antiseptics for no obvious reason. The utilization of antiseptics is determined by the availability of products provided within the institution and preferences of the clinician. Thus, it is unknown whether the chosen antiseptic has any bactericidal effect on the confirmed bacteria.

University Hospital RWTH Aachen Wound Care only uses polyhexanide and octenisept. Iodine-containing preparations are explicitly not desired.Improvement (bacteria reduction, acceleration of wound healing) of the local antiseptic therapy by adapting the antiseptic to the results of antimicrobial resistance testing. Antimicrobial resistance testing has so far only been used to adapt systemic antibiotic therapy.




18+ years old


No Healthy Volunteers

Inclusion criteria

  1. Age ≥ 18 years
  2. Decubitus OR secondary healing acute and chronic wounds
  3. Positively tested wound swab for bacteria (incl. multi-resistant bacteria)
  4. Patient is capable of understanding the nature, significance and consequence of the clinical trial
  5. Given written consent
  6. Women of child bearing potential (WOCBP) who apply appropriate methods of contraception throughout the duration of the study

Exclusion criteria

  1. Occlusive dressing (e.g. VAC) or Negative Pressure Wound Therapy (NPWT)
  2. Pregnant or lactating women
  3. Known allergies against investigational products

Trial design

Primary purpose




Interventional model

Parallel Assignment


None (Open label)

0 participants in 2 patient groups

Standard Care
No Intervention group
Octenisept will be used as standard care antiseptic for dressing change
Resistance testing
Experimental group
Patients will be first tested on resistance to Octenisept and Serasept and will receive the appropriate antiseptic after reviewing the results
Drug: Octenisept and Serasept

Trial contacts and locations



Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems